Condition: Metastatic Colorectal Cancer (CRC) · Recurrent Colorectal Cancer · Sponsor: STCube, Inc.
The objective of this multi-center, single-group, open-label Phase Ib/II study is to evaluate the safety, pharmacokinetics, and efficacy of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in metastatic or recurrent colorectal cancer patients with resistance or intolerance to oxaliplatin- and irinotecan-based chemotherapy, and to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and the efficacy and safety of the combination therapy in BTN1A1-positive patients.
This description comes directly from the study's public registry record.
Hyunju Yoo · +8225513370 · ID@stcube.com
Always discuss trial participation with your own doctor first.
| Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do, South Korea | Not Yet Recruiting |
| Seoul National University Hospital | Seoul, KR, South Korea | Not Yet Recruiting |
| Severance Hospital | Seoul, KR, South Korea | Not Yet Recruiting |
| Asan Medical Center | Seoul, KR, South Korea | Not Yet Recruiting |
| Korea University Anam Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06873763